3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Disruption of respiratory epithelial basement membrane in COVID-19 patients

      letter

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear Editor, Coronavirus SARS-CoV-2 has infected over 110 million people and the COVID-19 pandemic claimed more than 2.4 million lives worldwide as of February 17th, 2021. SARS-CoV-2 causes substantial pulmonary disease including pneumonia and acute respiratory distress syndrome (ARDS), especially in individuals at old age with multiple comorbidities and immunocompromisation [1]. The pathological features of COVID-19 lungs greatly resemble those seen in severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome (MERS) coronavirus infection. However, the pathogenesis of the disease is largely unclear. Pathological findings showed the typical features of diffuse alveolar damage (DAD) in SARS-CoV-2 caused ARDS [2]. Lung biopsy of a COVID-19 patient showed bilateral DAD with desquamation of pneumocytes, hyaline membrane formation, and alveolar edema [2]. SARS-CoV-2 infected ciliated cells in the airway and type 2 pneumocytes (AT2) in alveolar regions [3]. Viral particles can be detected in AT2 cells and KRT5+ airway cells [4]. Notably, a significant depletion of AT1 and increased proliferation of AT2 cells were observed, suggesting that AT2 cells are mobilized to regenerate the damaged alveoli in COVID-19 lungs [4]. In the trachea and large airways, KRT5+ cells proliferated extensively, while in smaller airways predominant proliferating cells were lineage undetermined [4]. Interstitial mononuclear inflammatory infiltrates, dominated by lymphocytes, were seen in biopsied lungs [2]. Recently, an array of extrapulmonary manifestations have been reported in many organs and tissues [5]. Recent reviews also suggest viral sepsis in COVID-19 patients, as well as endothelial dysfunction and thrombotic microangiopathy [1]. We think that these extrapulmonary manifestations can be explained by the failure of the respiratory epithelial cells and their basement membrane. In this letter, by immunofluorescence co-staining, we examined the integrity of the respiratory epithelium, endothelium and the respiratory epithelial basement membrane, and discovered the loss of respiratory epithelial integrity and the epithelial basement membrane in COVID-19 patients. The alveolar basement membrane is a critical component of blood–air barrier (BAB, or alveolar–capillary barrier) which prevents the formation of air bubbles in the blood, and from blood entering the alveoli. The alveolar basement membrane acts as scaffolds guiding morphogenesis, tissue repair, micromolecular permeability regulation, and cell movement. To demonstrate the structures and functions of the basement membranes in COVID-19 patients, we first examined COVID-19 lung sections from autopsies of three patients and three healthy donors (patient information was detailed in our previous study [4] and in supplemental materials). Immunoactivity of SARS-CoV-2 viral capsid spike (S) protein can be seen in the COVID-19 lung sections (Fig. 1a). Immunostaining for Laminin, the major component of basement membrane, on healthy lung sections gave clear and smooth basement membrane bands surrounding both alveoli and blood vessels (Fig. 1a, #1 and 2 areas). In COVID-19 lung sections, the alveolar and vascular structures were severely damaged, and the lumens were filled with nucleated and non-nucleated cells (Fig. 1a). Although positive Laminin staining could be detected in lung interstitial tissues, the bands were interrupted, and scattered Laminin protein was found in interstitial tissues. Moreover, fibrous Laminin was lining the alveolar-like structures in COVID-19 lung sections (Fig. 1a, area #3). Condensed cell areas were also identified (#4 area), suggesting fibrosis foci in COVID-19 lungs. Vascular-like round structures were found in these condensed cell areas (#3 and 4 areas) (Fig. 1a), suggesting vasculogenesis in those areas. These pathological changes can be found in all three cases of COVID-19 lungs (Supplementary Fig. 1). Fig. 1 Disrupted alveolar epithelial basement membrane in COVID-19 patient lung. a Immunofluorescence for basement membrane marker, Laminin, and SARS-CoV-2 viral capsid protein “spike” on healthy and COVID-19 lung sections. Two boxed areas were magnified in both healthy and COVID-19 lung sections. b Laminin γ3 staining on healthy and COVID-19 lung sections. More and less severely damaged areas of COVID-19 patient lung areas were boxed and magnified on tile scanning images. c Co-staining of Laminin and endothelial cells marker, CD31, on healthy and COVID-19 lung sections. The Laminin-stained basement membranes were shattered (arrows). Note that the endothelium of both pulmonary vein and capillaries in COVID-19 lung was interrupted (arrowheads). d Co-staining for Laminin and AT2 marker, HTII-280, on healthy and COVID-19 lung sections. Clear Laminin+ bands were observed underneath AT2 cells in healthy lung but not in COVID-19 lung (arrows). Magnified areas are boxed. Asterisks, AT2 cells desquamated from alveolar walls. Scale bars, 20 μm To further confirm epithelial basement membrane defects, we used another antibody to detect Laminin γ3 and observed similar staining structures in healthy lungs (Fig. 1b). In tile scanning COVID-19 sections, severely damaged lung structures and disrupted basement membrane bands were apparent. At higher magnifications, we found abnormal basement membrane structures in both severely damaged lung areas (#5 area) and less damaged areas (#6 area) (Fig. 1b). These observations were also confirmed in the other two COVOD-19 lungs. To better locate the basement membrane, we co-stained the endothelial cell marker, CD31, with Laminin. In healthy lung sections, the endothelium was either well lined in blood vessels (arrowhead) or was evenly distributed in the alveolar walls (boxed area) and was surrounded by Laminin+ basement membrane (Fig. 1c, arrows). In COVID-19 lung sections, CD31 showed much less immunostaining signal in alveolar areas, and vascular endothelium was also disrupted (arrowheads). More importantly, the basement membrane was severely damaged (Fig. 1c, arrows). We next examined AT2 cells and found dispersed HTII-280+ AT2 in healthy lung sections and smooth Laminin+ basement membrane right underneath AT2 cells (Fig. 1d, arrows). However, in COVID-19 sections, HTII-280+ cells were present in multiple cell clusters. Most AT2 cells were desquamated from the alveolar walls and were larger and more flattened compared to healthy AT2 cells (Fig. 1d, asterisks and arrows). The expression levels of laminin were lower in the alveolar walls and were barely detected in AT2 regions, suggesting damaged AT2 cell basement membrane (Fig. 1d). These pathological changes could be found in all three cases of COVID-19 lungs. Taken together, we demonstrate that SARS-CoV-2 caused severe damage to the human lung. Cell-filled alveoli and condensed fibrosis-like cell regions are identified in COVID-19 lungs. The alveolar endothelium is severely damaged and the epithelial cell boundaries (BABs) are broken, leading to the inflow of cells and viral particles from the lung alveoli into blood. AT2 cells accumulate to form colonies and most cells are desquamated from the alveoli-like structures and exhibit altered cell morphologies. Most interestingly, the alveolar basement membranes, including epithelial and vascular basement membranes, are severely disrupted. Scattered and disconnected basement membrane components were identified in COVID-19 lungs. All these damages resembled the changes in alveolar and microvascular endothelial structure ARDS. We speculate that when the dams (the respiratory epithelial cells and their basement membrane) are breached, the flood (viral particles) can reach other organs, tissues, and cells which usually would not see the virus. Because of the heterogeneous nature of the “flood”, a wide array of extrapulmonary manifestations then present. These findings provide pathological insights in understanding the mechanisms of alveolar damage and alveolar repair. Further investigations into the underlying mechanisms of alveolar regeneration and basement membrane repair should help in developing strategies for combating lung damage as well as extrapulmonary injuries in COVID-19 patients. Also, in coordinate with the systemic inflammatory response induced “cytokine storm” and thromboembolism in COVID-19 patients, severity of basement membrane damage is likely to be a possible factor to clinical severity and mortality. Supplementary Information Additional file 1. Supplementary Information for Materials and Methods. Supplementary Fig.1. Laminin staining on three COVID-19 patients and one normal lung sections.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: found
          • Article: not found

          Pathological findings of COVID-19 associated with acute respiratory distress syndrome

          Since late December, 2019, an outbreak of a novel coronavirus disease (COVID-19; previously known as 2019-nCoV)1, 2 was reported in Wuhan, China, 2 which has subsequently affected 26 countries worldwide. In general, COVID-19 is an acute resolved disease but it can also be deadly, with a 2% case fatality rate. Severe disease onset might result in death due to massive alveolar damage and progressive respiratory failure.2, 3 As of Feb 15, about 66 580 cases have been confirmed and over 1524 deaths. However, no pathology has been reported due to barely accessible autopsy or biopsy.2, 3 Here, we investigated the pathological characteristics of a patient who died from severe infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by postmortem biopsies. This study is in accordance with regulations issued by the National Health Commission of China and the Helsinki Declaration. Our findings will facilitate understanding of the pathogenesis of COVID-19 and improve clinical strategies against the disease. A 50-year-old man was admitted to a fever clinic on Jan 21, 2020, with symptoms of fever, chills, cough, fatigue and shortness of breath. He reported a travel history to Wuhan Jan 8–12, and that he had initial symptoms of mild chills and dry cough on Jan 14 (day 1 of illness) but did not see a doctor and kept working until Jan 21 (figure 1 ). Chest x-ray showed multiple patchy shadows in both lungs (appendix p 2), and a throat swab sample was taken. On Jan 22 (day 9 of illness), the Beijing Centers for Disease Control (CDC) confirmed by reverse real-time PCR assay that the patient had COVID-19. Figure 1 Timeline of disease course according to days from initial presentation of illness and days from hospital admission, from Jan 8–27, 2020 SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. He was immediately admitted to the isolation ward and received supplemental oxygen through a face mask. He was given interferon alfa-2b (5 million units twice daily, atomisation inhalation) and lopinavir plus ritonavir (500 mg twice daily, orally) as antiviral therapy, and moxifloxacin (0·4 g once daily, intravenously) to prevent secondary infection. Given the serious shortness of breath and hypoxaemia, methylprednisolone (80 mg twice daily, intravenously) was administered to attenuate lung inflammation. Laboratory tests results are listed in the appendix (p 4). After receiving medication, his body temperature reduced from 39·0 to 36·4 °C. However, his cough, dyspnoea, and fatigue did not improve. On day 12 of illness, after initial presentation, chest x-ray showed progressive infiltrate and diffuse gridding shadow in both lungs. He refused ventilator support in the intensive care unit repeatedly because he suffered from claustrophobia; therefore, he received high-flow nasal cannula (HFNC) oxygen therapy (60% concentration, flow rate 40 L/min). On day 13 of illness, the patient's symptoms had still not improved, but oxygen saturation remained above 95%. In the afternoon of day 14 of illness, his hypoxaemia and shortness of breath worsened. Despite receiving HFNC oxygen therapy (100% concentration, flow rate 40 L/min), oxygen saturation values decreased to 60%, and the patient had sudden cardiac arrest. He was immediately given invasive ventilation, chest compression, and adrenaline injection. Unfortunately, the rescue was not successful, and he died at 18:31 (Beijing time). Biopsy samples were taken from lung, liver, and heart tissue of the patient. Histological examination showed bilateral diffuse alveolar damage with cellular fibromyxoid exudates (figure 2A, B ). The right lung showed evident desquamation of pneumocytes and hyaline membrane formation, indicating acute respiratory distress syndrome (ARDS; figure 2A). The left lung tissue displayed pulmonary oedema with hyaline membrane formation, suggestive of early-phase ARDS (figure 2B). Interstitial mononuclear inflammatory infiltrates, dominated by lymphocytes, were seen in both lungs. Multinucleated syncytial cells with atypical enlarged pneumocytes characterised by large nuclei, amphophilic granular cytoplasm, and prominent nucleoli were identified in the intra-alveolar spaces, showing viral cytopathic-like changes. No obvious intranuclear or intracytoplasmic viral inclusions were identified. Figure 2 Pathological manifestations of right (A) and left (B) lung tissue, liver tissue (C), and heart tissue (D) in a patient with severe pneumonia caused by SARS-CoV-2 SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. The pathological features of COVID-19 greatly resemble those seen in SARS and Middle Eastern respiratory syndrome (MERS) coronavirus infection.4, 5 In addition, the liver biopsy specimens of the patient with COVID-19 showed moderate microvesicular steatosis and mild lobular and portal activity (figure 2C), indicating the injury could have been caused by either SARS-CoV-2 infection or drug-induced liver injury. There were a few interstitial mononuclear inflammatory infiltrates, but no other substantial damage in the heart tissue (figure 2D). Peripheral blood was prepared for flow cytometric analysis. We found that the counts of peripheral CD4 and CD8 T cells were substantially reduced, while their status was hyperactivated, as evidenced by the high proportions of HLA-DR (CD4 3·47%) and CD38 (CD8 39·4%) double-positive fractions (appendix p 3). Moreover, there was an increased concentration of highly proinflammatory CCR6+ Th17 in CD4 T cells (appendix p 3). Additionally, CD8 T cells were found to harbour high concentrations of cytotoxic granules, in which 31·6% cells were perforin positive, 64·2% cells were granulysin positive, and 30·5% cells were granulysin and perforin double-positive (appendix p 3). Our results imply that overactivation of T cells, manifested by increase of Th17 and high cytotoxicity of CD8 T cells, accounts for, in part, the severe immune injury in this patient. X-ray images showed rapid progression of pneumonia and some differences between the left and right lung. In addition, the liver tissue showed moderate microvesicular steatosis and mild lobular activity, but there was no conclusive evidence to support SARS-CoV-2 infection or drug-induced liver injury as the cause. There were no obvious histological changes seen in heart tissue, suggesting that SARS-CoV-2 infection might not directly impair the heart. Although corticosteroid treatment is not routinely recommended to be used for SARS-CoV-2 pneumonia, 1 according to our pathological findings of pulmonary oedema and hyaline membrane formation, timely and appropriate use of corticosteroids together with ventilator support should be considered for the severe patients to prevent ARDS development. Lymphopenia is a common feature in the patients with COVID-19 and might be a critical factor associated with disease severity and mortality. 3 Our clinical and pathological findings in this severe case of COVID-19 can not only help to identify a cause of death, but also provide new insights into the pathogenesis of SARS-CoV-2-related pneumonia, which might help physicians to formulate a timely therapeutic strategy for similar severe patients and reduce mortality. This online publication has been corrected. The corrected version first appeared at thelancet.com/respiratory on February 25, 2020
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Extrapulmonary manifestations of COVID-19

            Although COVID-19 is most well known for causing substantial respiratory pathology, it can also result in several extrapulmonary manifestations. These conditions include thrombotic complications, myocardial dysfunction and arrhythmia, acute coronary syndromes, acute kidney injury, gastrointestinal symptoms, hepatocellular injury, hyperglycemia and ketosis, neurologic illnesses, ocular symptoms, and dermatologic complications. Given that ACE2, the entry receptor for the causative coronavirus SARS-CoV-2, is expressed in multiple extrapulmonary tissues, direct viral tissue damage is a plausible mechanism of injury. In addition, endothelial damage and thromboinflammation, dysregulation of immune responses, and maladaptation of ACE2-related pathways might all contribute to these extrapulmonary manifestations of COVID-19. Here we review the extrapulmonary organ-specific pathophysiology, presentations and management considerations for patients with COVID-19 to aid clinicians and scientists in recognizing and monitoring the spectrum of manifestations, and in developing research priorities and therapeutic strategies for all organ systems involved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              SARS-CoV-2 and viral sepsis: observations and hypotheses

              Summary Since the outbreak of coronavirus disease 2019 (COVID-19), clinicians have tried every effort to understand the disease, and a brief portrait of its clinical features have been identified. In clinical practice, we noticed that many severe or critically ill COVID-19 patients developed typical clinical manifestations of shock, including cold extremities and weak peripheral pulses, even in the absence of overt hypotension. Understanding the mechanism of viral sepsis in COVID-19 is warranted for exploring better clinical care for these patients. With evidence collected from autopsy studies on COVID-19 and basic science research on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV, we have put forward several hypotheses about SARS-CoV-2 pathogenesis after multiple rounds of discussion among basic science researchers, pathologists, and clinicians working on COVID-19. We hypothesise that a process called viral sepsis is crucial to the disease mechanism of COVID-19. Although these ideas might be proven imperfect or even wrong later, we believe they can provide inputs and guide directions for basic research at this moment.
                Bookmark

                Author and article information

                Contributors
                Dianhua.Jiang@CSHS.org
                Journal
                Mol Biomed
                Molecular Biomedicine
                Springer Singapore (Singapore )
                2662-8651
                20 March 2021
                20 March 2021
                2021
                : 2
                : 1
                : 8
                Affiliations
                [1 ]GRID grid.50956.3f, ISNI 0000 0001 2152 9905, Department of Medicine, Division of Pulmonary and Critical Care Medicine, , Women’s Guild Lung Institute, Cedars-Sinai Medical Center, ; Los Angeles, California USA
                [2 ]GRID grid.239585.0, ISNI 0000 0001 2285 2675, Center for Human Development and Division of Digestive and Liver Disease, Department of Medicine, , Columbia University Medical Center, ; New York, NY 10032 USA
                [3 ]GRID grid.50956.3f, ISNI 0000 0001 2152 9905, Department of Biomedical Sciences, , Cedars-Sinai Medical Center, ; Los Angeles, California USA
                Article
                31
                10.1186/s43556-021-00031-6
                7979449
                34766002
                cb3b0b7b-edcd-4472-8127-76af7de3621a
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 9 January 2021
                : 22 February 2021
                Funding
                Funded by: Foundation for the National Institutes of Health (US)
                Award ID: HL108793
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000009, Foundation for the National Institutes of Health;
                Award ID: HL132996
                Award ID: HL152293
                Award Recipient :
                Categories
                Letter
                Custom metadata
                © The Author(s) 2021

                Comments

                Comment on this article